Role of tumor necrosis factor-α and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women
- 1 October 2001
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 88 (7), 825-828
- https://doi.org/10.1016/s0002-9149(01)01865-3
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of inflammation in postmenopausal womenThe American Journal of Cardiology, 2000
- Elevation of Tumor Necrosis Factor-α and Increased Risk of Recurrent Coronary Events After Myocardial InfarctionCirculation, 2000
- Plasma Concentration of Interleukin-6 and the Risk of Future Myocardial Infarction Among Apparently Healthy MenCirculation, 2000
- C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in WomenNew England Journal of Medicine, 2000
- Hormone Replacement Therapy and Increased Plasma Concentration of C-Reactive ProteinCirculation, 1999
- Effect of Postmenopausal Hormones on Inflammation-Sensitive ProteinsCirculation, 1999
- Hormone Replacement Therapy, Inflammation, and Hemostasis in Elderly WomenArteriosclerosis, Thrombosis, and Vascular Biology, 1999
- Hormone and Nonhormone Therapy for the Maintenance of Postmenopausal Health: The Need for Randomized Controlled Trials of Estrogen and RaloxifeneJournal of Women's Health, 1998
- Effects of Raloxifene on Serum Lipids and Coagulation Factors in Healthy Postmenopausal WomenJAMA, 1998
- The acute phase responseImmunology Today, 1994